Merck’s acquisition of Afferent Pharmaceuticals provides platform into IPF market
![](/46/pdcnewsitem/04/14/57/GDnewlogo.jpg)
The deal will mean Merck acquires Afferent’s lead candidate, AF-219, which is currently in Phase II trials in IPF patients with persistent cough, says GlobalData.
Merck’s acquisition of privately held company Afferent Pharmaceuticals will provide it with an entry-platform into the fast-growing idiopathic pulmonary fibrosis (IPF) market, which is forecast to reach $3.2 billion by 2025, according to an analyst with research and consulting firm GlobalData.
The agreement terms state that Merck, through a subsidiary, will acquire all outstanding stock of Afferent in exchange for a payment of $500 million in cash up front. The company will acquire Afferent’s lead candidate, AF-219, a selective, non-narcotic, orally-administered P2X3 antagonist, which is currently in Phase II trials in IPF patients with persistent cough.
Matthew Thaxter, MSc, GlobalData’s Analyst covering Immunology, explains: “At the 2016 American Thoracic Society’s annual conference in May, Afferent presented data from its Phase IIb chronic cough study that showed treatment with AF-219 significantly reduced cough frequency at all doses. Afferent also states that 73–86% of IPF patients suffer from chronic cough, and the two currently approved IPF treatments — Genentech’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) — do not alleviate any disease-associated symptoms.”
As explored in GlobalData’s latest IPF report, licensing agreements, alliances and acquisitions have emerged as key trends in the IPF market. Merck is the latest company to enter the space through this method, but not the first. In August 2014, Roche acquired Genentech, and in August 2015, Bristol-Myers Squibb entered an agreement giving it exclusive rights to acquire Promedior and its lead asset for IPF, PRM-151.
Thaxter continues: “Despite Merck’s acquisition of Afferent providing the company with a way in to the IPF market, AF-219, if approved, will be restricted by the fact that it has no impact on the progression of IPF itself. As such, AF-219 is very unlikely to demand the high price premiums of Esbriet and Ofev, which are both over $90,000 annually.
“Still, there does exist a large patient base for AF-219, with over 107,000 diagnosed prevalent IPF cases in patients aged 50 or above in the seven major markets of the US, Germany, France, Spain, Italy, the UK, and Japan. AF-219’s large target population will act to offset its low price, and GlobalData anticipates its sales volumes will be higher if the product gains regulatory approval.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance